

APR 14 2005

K050532

**SPI GLOVES SDN. BHD.**

5, Persiaran Greentown 8, Greentown Business Centre,  
30450 Ipoh, Perak Darul Ridzuan, Malaysia.  
e-mail: info@sealpolymer.com.my

**1.0**

**SMDA 510 (K) SUMMARY**

**2.0**

**Submitter**

SPI GLOVES SDN. BHD.  
5, Persiaran Greentown 8,  
Greentown Business Centre,  
30450 Ipoh, Perak, Malaysia.

Tel

(60 5) 322 3200

Fax

(60 5) 322 2300

Name of Contact Person

Ms. CHUN CHOOI FONG

Date of Summary Prepared

February 7, 2005

**3.0**

**Name of Device**

Device Name

Chlorinated Powder Free Latex Examination Gloves

Common Name

Exam Glove

Classification Name

Latex Patient Examination Glove

**4.0**

**Identification of the Legally Marketed Devices**

Class 1 Latex Patient Examination Glove 80LYY, powder free that meets all the requirements of ASTM Standard D3578-01a<sup>E2</sup> and FDA requirements.

**5.0**

**Description of The Device**

Class 1 Latex Patient Examination Glove 80LYY, powder free that meets all the requirements of ASTM Standard D3578-01a<sup>E2</sup> and FDA Water Leak Test.

**6.0**

**The Intended Use of Glove**

A patient examination glove is a disposable device intended for medical purposes that is worn on the examiner's hands or finger to prevent contamination between patient and examiner.

**SPI GLOVES SDN. BHD.**  
5, Persiaran Greentown 8, Greentown Business Centre,  
30450 Ipoh, Perak Darul Ridzuan, Malaysia.  
e-mail: info@sealpolymer.com.my

**7. Summary of Performance Data:**

Performance data of gloves based on ASTM D3578-01a<sup>E2</sup> and FDA 1000 ml watertight test.

TEST	ASTM D3578-01a <sup>E2</sup>	CHLORINATED POWDER FREE LATEX EXAM GLOVES
1. Watertight (1000 ml)	G I AQL=2.5%	Pass GI AQL=2.5%
2. Length (mm) Size XS S M L XL	Min 230 Min 230 Min 230 Min 230 Min 230	240 mm minimum for all sizes
3. Palm width (mm) Size XS S M L XL	- 80 +/- 10 95 +/- 10 111 +/- 10 -	<80 mm 85 +/- 3 mm 95 +/- 3 mm 105 +/- 3 mm >110 mm
4. Thickness (mm) (Single Layer)  Finger Palm	Min 0.08 Min 0.08	0.10 minimum 0.10 minimum
5. Physical Properties  <b>Before Aging</b> Tensile Strength (Mpa) Ultimate Elongation (%)  <b>After Aging</b> Tensile Strength (Mpa) Ultimate Elongation (%)	Min 14.0 Min 650  Min 14.0 Min 500	*19.9 *835  *16.5 *786
6. Powder Content	-	Below 2mg / glove
7. Protein Content	-	Below 50 microgram / gram

\* The average results obtain from Attachment C.

**SPI GLOVES SDN. BHD.**

5, Persiaran Greentown 8, Greentown Business Centre,  
30450 Ipoh, Perak Darul Ridzuan, Malaysia.  
e-mail: info@sealpolymer.com.my

8. The performance data of the glove as showed above meet the ASTM D3578-01a<sup>E2</sup> Standard and FDA's requirement.  
Powder content is below 2mg per glove, which meet the FDA Requirements.

9. The Biocompatibility Test consists of Primary Dermal Irritation Test and Guinea Pig Sensitization (Buehler) test.  
The gloves pass the Biocompatibility Tests.

10. Conclusion

We concluded that the Chlorinated Powder Free Latex Examination Gloves meet the below specifications:

- ASTM D3578-01a<sup>E2</sup> Standard
- FDA pinhole requirements
- FDA minimum powder residual content



APR 14 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ms. Chun Chooi Fong  
Quality Management System Manager  
SPI Gloves SND. BHD.  
5, Persiaran Greentown 8,  
Greentown Business Centre,  
30450 Ipoh, Perak, Darul Ridzuan  
MALAYSIA

Re: K050532  
Trade/Device Name: Chlorinated Powder Free Latex Examination Gloves with  
Protein Labeling Claim (Contains 50 Micrograms or Less of Total Water Extractable  
Protein Per Gram)  
Regulation Number: 880.6250  
Regulation Name: Patient Examination Glove  
Regulatory Class: I  
Product Code: LYY  
Dated: February 28, 2005  
Received: March 2, 2005

Dear Ms. Chooi Fong:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Chiu Lin', with a stylized flourish at the end.

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

## Page 5